JP Morgan Chase
PCVX icon

JP Morgan Chase’s Vaxcyte PCVX Stock Holding History

JP Morgan Chase’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.2M Buy
1,227,346
+219,032
+22% +$11.9M ﹤0.01% 1233
2026
Q1 		$55.4M Sell
1,008,314
-77,205
-7% -$4.19M ﹤0.01% 1333
2025
Q4 		$50.1M Sell
1,085,519
-479,517
-31% -$21.4M ﹤0.01% 1367
2025
Q3 		$56.4M Buy
1,565,036
+366,266
+31% +$12.1M ﹤0.01% 1336
2025
Q2 		$39M Sell
1,198,770
-701,409
-37% -$23M ﹤0.01% 1481
2025
Q1 		$71.8M Buy
1,900,179
+164,516
+9% +$13.2M 0.01% 1101
2024
Q4 		$142M Buy
1,735,663
+307,903
+22% +$30.6M 0.01% 790
2024
Q3 		$163M Buy
1,427,760
+215,317
+18% +$19.4M 0.01% 764
2024
Q2 		$91.6M Buy
1,212,443
+50,666
+4% +$3.45M 0.01% 946
2024
Q1 		$79.4M Buy
1,161,777
+756,443
+187% +$52.4M 0.01% 1050
2023
Q4 		$25.5M Sell
405,334
-232,387
-36% -$12.1M ﹤0.01% 1649
2023
Q3 		$32.5M Buy
637,721
+281,312
+79% +$13.9M ﹤0.01% 1339
2023
Q2 		$17.8M Buy
356,409
+63,513
+22% +$3.01M ﹤0.01% 1788
2023
Q1 		$11M Buy
292,896
+39,964
+16% +$1.7M ﹤0.01% 2191
2022
Q4 		$12.1M Buy
252,932
+72,805
+40% +$2.86M ﹤0.01% 2079
2022
Q3 		$4.32M Buy
180,127
+135,955
+308% +$3.45M ﹤0.01% 2864
2022
Q2 		$961K Buy
44,172
+17,380
+65% +$402K ﹤0.01% 4128
2022
Q1 		$647K Buy
26,792
+6,390
+31% +$140K ﹤0.01% 4538
2021
Q4 		$486K Sell
20,402
-5,655
-22% -$132K ﹤0.01% 4862
2021
Q3 		$661K Buy
26,057
+4,176
+19% +$101K ﹤0.01% 4567
2021
Q2 		$493K Sell
21,881
-43,064
-66% -$882K ﹤0.01% 4706
2021
Q1 		$1.28M Buy
64,945
+27,454
+73% +$691K ﹤0.01% 4038
2020
Q4 		$996K Buy
37,491
+30,703
+452% +$1.14M ﹤0.01% 3971
2020
Q3 		$350K Buy
+6,788
New +$270K ﹤0.01% 4135

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

JP Morgan Chase's PCVX Position: Q2 2026 in Review

JP Morgan Chase increased its Vaxcyte (PCVX) stake by 22% in Q2 2026, buying an estimated $11.9M and bringing the position to 1,227,346 shares worth $71.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1233.

JP Morgan Chase first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $163M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • JP Morgan Chase held 1,227,346 shares of Vaxcyte worth $71.2M as of Q2 2026.
  • JP Morgan Chase bought 219,032 Vaxcyte shares in Q2 2026, an estimated $11.9M.
  • Vaxcyte made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1233 holding.
  • JP Morgan Chase first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Vaxcyte position peaked at $163M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.